iOncologi

iOncologi is a private, pre-revenue biotech founded in 2018, advancing a novel class of RNA therapeutics designed to overcome resistance to immune checkpoint inhibitors across solid tumors. The company's strategy is built on its UNIFYRs™ platform and proprietary nanoparticle delivery systems, validated by foundational IP and publications in high-impact journals. A key recent partnership with SandboxAQ aims to use AI to accelerate the development of a therapy for glioblastoma, highlighting its deep-tech approach. With a pipeline in early clinical stages, iOncologi is positioning itself at the intersection of RNA biology, immunotherapy, and artificial intelligence.

UNIFYRs™ (Universal Immune Fortifying RNAs) platform of RNA-based formulations to reprogram systemic and intratumoral immunity; proprietary precision lipid-based multilamellar nanocomplexes (tumor-targeting biodrones) for payload delivery; cell-mediated immune reset platform; integrated AI/ML design via partnerships.

iOncologi competes in the crowded immuno-oncology sector, specifically the sub-segment focused on overcoming resistance to checkpoint inhibitors. Competitors range from large pharma (e.g., Merck, Roche, BMS) developing their own combinations to numerous biotechs targeting the tumor microenvironment with small molecules, antibodies, and cell therapies. Its differentiation lies in its specific RNA approach, proprietary nanoparticle delivery, and deep integration of AI for drug design.